Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24500703 | 0.85 | PPARA (0.39) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL29711746 | 0.84 | PPARA (0.37) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL29711764 | 0.84 | PPARA (0.37) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL24496961 | 0.84 | PPARA (0.37) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL22425737 | 0.81 | PPARA (0.47) | PPARAPPARGCTSSAAK1CA2 | |
| SCHEMBL22425939 | 0.81 | PPARA (0.47) | PPARAPPARGCTSSAAK1CA2 | |
| SCHEMBL22425744 | 0.81 | PPARA (0.47) | PPARAPPARGCTSSAAK1CA2 | |
| SCHEMBL24500229 | 0.77 | P2RX3 (0.31) | — | |
| SCHEMBL24500822 | 0.77 | PPARA (0.40) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL18862943 | 0.76 | TRPA1 (0.46) | AAK1TRPA1CA2CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | PPARA 2062/4885PPARG 2574/4885CTSS 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.